Cellectis bioresearch Announces Establishment of Subsidiary in the US
PARIS, Oct. 13 /PRNewswire/ -- Cellectis bioresearch, a specialist in genome customization and subsidiary of Cellectis (Alternext: ALCLS), today announced that it has established a US subsidiary, Cellectis bioresearch Inc. Located at the Cambridge Innovation Center in Cambridge, Massachusetts, Cellectis bioresearch Inc. will be responsible for the US-wide promotion of Cellectis bioresearch products and services.
Cellectis bioresearch's portfolio today offers over 100 product references, fitting the major needs for genome customization of the life science community. These products include its cellular Genome Positioning System (cGPS®) and cGPS® Custom targeted integration kits, which enable the engineering of cell lines with optimized features for drug discovery, protein production and gene function studies.
Eric Merle will serve as Sales Director US. His strong experience in the research tool area in the United States will be a valuable asset in the launch of Cellectis bioresearch Inc.'s operations. Eric Merle will be in charge of recruiting and managing a dedicated team, covering the entire US market. He will report to Luc Selig, VP Sales & Marketing at Cellectis bioresearch.
"Cellectis bioresearch's goal is to make its genome customization products the gold standard for the life sciences community worldwide," explains Luc Selig. "The opening of our American subsidiary will provide us with a presence in the largest global Life Science market and allow us to be closer to our clients to better meet their needs."
Together with the recently announced partnership with the Canadian Life Science products distributor Cedarlane Inc., the creation of Cellectis bioresearch Inc. will establish a foothold for Cellectis bioresearch in the North American market.
About Cellectis bioresearch
Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides